Publication

Estimating the Impact of Asthma and COPD on Lung Cancer Screening in the USA

Nielsen, Natalia
Ballinger, Zack
Muñoz Villarreal, Blanca
Kovell, Lara
Ito Fukunaga, Mayuko
Castañeda-Avila, Maira
Embargo Expiration Date
Abstract

Objectives: Examine the association of asthma, COPD, and Asthma-COPD overlap (ACO) on rates of lung cancer screening.

Methods: 2022 Behavior and Risk Factors Surveillance Survey was used for cross-sectional analysis of self-reported lung cancer screening prevalence in those with COPD, asthma, and ACO, with stratification by smoking status. Multivariate logistic regression was performed to assess the relationship between asthma, COPD, ACO and lung cancer screening status.

Results: 17.9% of eligible adults were up-to-date on lung cancer screening. Those with COPD and ACO had higher rates of ever undergoing lung cancer screening (50.8% and 47.5%) than those with asthma (26.4%) or neither condition (23%). Adults with COPD (adjusted odds ratios (aOR): 2.86, 95% CI 2.49-3.28) and ACO (aOR: 2.85, 95% CI 2.49-3.28) had increased odds of ever having lung cancer screening compared with those without either condition. Stratification by smoking status shows that individuals who formerly smoked had slightly higher odds of ever undergoing screening than individuals currently smoking.

Conclusion: Lung cancer screening rates have increased; however, it remains low. Adults with COPD and ACO are more likely to undergo lung cancer screening.

Source

Nielsen N, Ballinger Z, Muñoz Villarreal B, Kovell L, Ito Fukunaga M, Castañeda-Avila M. Estimating the Impact of Asthma and COPD on Lung Cancer Screening in the USA. Lung. 2024 Nov 27;203(1):2. doi: 10.1007/s00408-024-00771-6. PMID: 39601881.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1007/s00408-024-00771-6
PubMed ID
39601881
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Distribution License